Frates James M's Form 4 filing
Amylyx Pharmaceuticals, Inc. (AMLX) · filed Sep 16, 2024
- Accession no.
- 0000950170-24-106910
- Filed
- Sep 16, 2024
- Trade date
- Sep 12, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $101.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Frates James MCIK 0001235598 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2024 | Common Stock | PPurchaseAcquired | +40,000 | $2.53F1 | +$101,200 | 233,464 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.4849 to $2.63. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.